Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Gene Silencing/Gene Editing » Correction: Feb 4, 2005

Correction: Feb 4, 2005

Feb 04, 2005
Premium

RNAi News incorrectly reported last week that CytRx CEO Steven Kriegsman had stated than an investigational new drug application for an siRNA-based amyotrophic lateral sclerosis treatment is expected to be filed in the second half of 2005.

Although the company’s earlier goal of filing an IND before the end of 2004 was dropped, a new timeline has not been established.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Severity Predictor

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

Pasteur Ends Vaccine Push

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

Shift Younger

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

Cell Studies on COVID-19 Autopsy Proteomics, Human Intestinal Development, Macaque Brain Map

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.